Lupin Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

According to an exchange filing, the agreement strengthens Lupin?s diabetes portfolio and expands its presence in the obesity segment. Bofanglutide, developed by Gan & Lee, is intended for adults with type 2 diabetes and for weight management in overweight or obese individuals. As a potential first-in-class fortnightly GLP-1 agonist, clinical data indicate that Bofanglutide delivers weight loss results comparable to or better than existing GLP-1 alternatives, with the added convenience of once-every-two-weeks dosing compared to weekly injections, while maintaining safety and tolerability consistent with the GLP-1 class. The drug also helps reduce blood glucose levels and body weight.

The company said obesity is emerging as a major health concern in India, with an estimated 174 million adults overweight and around 50 million classified as obese. Diabetes affects approximately 90 million adults in the country. Under the terms of the agreement, Lupin will have exclusive rights to commercialize and distribute Bofanglutide in India.

Nilesh Gupta, Managing Director, Lupin, said, ?We are committed to offering the best solutions for managing chronic metabolic diseases like diabetes, and addressing obesity is one of the most urgent global health challenges. This partnership demonstrates our strategic focus on the GLP-1 class of drugs and highlights our dedication to delivering high-quality, innovative therapies for our patients.?

Rajeev Sibal, President of India Region Formulations at Lupin, said, ?Bofanglutide offers a significant advantage with its convenient fortnightly dosing, thus reducing the number of injections by 50% while delivering outcomes and clinically proven efficacy that matches or surpasses existing weekly formulations. This strategic alliance marks a pivotal step in strengthening Lupin?s leadership in metabolic health, expanding our innovative portfolio, and reaffirming our commitment to delivering transformative solutions.?

Gan & Lee Executive Vice President & Chief Commercial Officer (EVP & CCO) Kai Du and Key Accounts Director, Dr Dhaval Soneji commented and believed, ?On the heels of the Latin American exclusive agreement signed in November, this new partnership with Lupin for the Indian market further underscores Gan & Lee?s rapid global strategic advancement. Our goal is to provide superior treatment options for patients with metabolic diseases worldwide, while showcasing the value of Chinese biopharmaceutical innovation on the global stage.?

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company had reported a 73.33% surge in consolidated net profit to Rs 1,477.92 crore in Q2 FY26 as against Rs 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025.

The counter rose 0.11% to currently trade at Rs 2,081.80 on the BSE.

Powered by Capital Market - Live News

Lupin has entered into an exclusive License, Supply and Distribution agreement with Gan & Lee Pharmaceuticals, headquartered in China, for a novel fortnightly GLP-1 receptor agonist, Bofanglutide.

The agreement strengthens Lupin's diabetes portfolio and accelerates its presence in the obesity segment. Bofanglutide injection is a fortnightly (once in two weeks) GLP-1 receptor agonist developed by Gan & Lee, intended for treating adults with type 2 diabetes and aiding weight management in overweight or obese individuals. As a potential first-in-class global fortnightly GLP-1 agonist, clinical data demonstrate that the weight loss results of Bofanglutide are comparable to or better than those of existing GLP-1 alternatives while offering the convenience of once in two weeks versus once a week for other injectable alternatives, and maintaining safety and tolerability consistent with the GLP-1 class. It effectively reduces both blood glucose levels and body weight.

Obesity is anticipated to develop into a significant health crisis in India, with approximately 174 million adults classified as overweight and around 50 million as obese. Diabetes is already considered an epidemic, with approximately 90 million adults affected by the condition. Under the terms of the agreement, Lupin will have exclusive rights to commercialize and distribute Bofanglutide in India.

Powered by Capital Market - Live News

The EIR was issued following an inspection of the facility from 08 September 2025 to 16 September 2025.

Nilesh Gupta, managing director, Lupin, said: ?We are pleased to have received the EIR from the U.S. FDA with a VAI classification for our Nagpur injectable facility.

We are committed to upholding the highest standards of quality and compliance across our facilities, with continued focus on enhancements to our quality systems and operational excellence.?

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The company had reported a 73.33% surge in consolidated net profit to Rs 1,477.92 crore in Q2 FY26 as against Rs 852.63 crore posted in Q2 FY25. Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025.

The counter rose 0.84% to currently trade at Rs 2107.20 on the BSE.

Powered by Capital Market - Live News

Lupin announced that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). These validations cover all three emission scopes ?V Scope 1, Scope 2, and Scope 3 - aligning with the Paris Agreement to limit global temperature rise to 1.5?XC.

This milestone underscores Lupin??s commitment to sustainability and decisive climate action, positioning the company among a select group that has achieved comprehensive SBTi validation within a year of setting its climate targets.

Key short-term targets:

?h - Reduce absolute Scope 1 and 2 greenhouse gas emissions by 42.0% by FY 2030, with FY 2023 as the base year.

?h - Reduce Scope 3 greenhouse gas emissions by 61.07% by FY 2033, across purchased goods and services, fuel- and energy-related activities, upstream and downstream transportation and distribution, business travel, employee commuting, processing and use of sold products, and franchises, using FY 2024 as the baseline.

These goals are aligned with the 1.5?XC pathway and validated under SBTi??s latest guidelines, thereby positioning Lupin as a key participant in the global effort to combat climate change.

Powered by Capital Market - Live News